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Abstract
In this report, we challenge a common perception that
tumor embolism is a size-limited event of mechanical
arrest, occurring in the first capillary bed encountered
by blood-borne metastatic cells. We tested the hy-
pothesis that mechanical entrapment alone, in the
absence of tumor cell adhesion to blood vessel walls,
is not sufficient for metastatic cell arrest in target
organ microvasculature. The in vivometastatic deposit
formation assay was used to assess the number and
location of fluorescently labeled tumor cells lodged
in selected organs and tissues following intravenous
inoculation. We report that a significant fraction of
breast and prostate cancer cells escapes arrest in a lung
capillary bed and lodges successfully in other organs
and tissues. Monoclonal antibodies and carbohydrate-
based compounds (anti–Thomsen-Friedenreich anti-
gen antibody, anti–galectin-3 antibody, modified citrus
pectin, and lactulosyl-L-leucine), targeting specifically
B-galactoside–mediated tumor–endothelial cell adhe-
sive interactions, inhibited by >90% the in vivo for-
mation of breast and prostate carcinoma metastatic
deposits in mouse lung and bones. Our results indi-
cate that metastatic cell arrest in target organ microves-
sels is not a consequence of mechanical trapping, but is
supported predominantly by intercellular adhesive in-
teractions mediated by cancer-associated Thomsen-
Friedenreich glycoantigen and B-galactoside–binding
lectin galectin-3. Efficient blocking of B-galactoside–
mediated adhesion precludes malignant cell lodging
in target organs.
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Introduction
The current vision of the process of hematogenous cancer
metastasis is based largely on two fundamental premises:
the mechanical trapping theory and the seed and soil hypo-
thesis, suggested by James Ewing and Stephen Paget, and
further enhanced and developed by Isaiah J. Fidler, Lance A.
Liotta, Garth Nicolson, and others (reviewed in Refs. [1,2]).
Recent advances in intravital video microscopy techniques
shed light onto numerous critical steps in tumor metasta-
sis [3–9], suggesting that early metastasis–associated
events, including initial micrometastases growth, may occur
entirely intravascularly [3–5]. Nevertheless, despite exten-
sive investigative efforts, several important questions related
to how tumor cells lodge in a target organ vasculature re-
main unresolved.
For example, based on video microscopic observations,
several groups suggested that metastatic cell arrest is a
highly efficient, strictly mechanical process occurring in the
first capillary bed encountered due to size limitation [5–7].
Thus, many view mechanical tumor embolism as an ultimate
cause of metastatic deposit formation. However, recent re-
sults from Vantyghem et al. [8] documented the development
of macroscopic extrapulmonary metastasis in the ovaries,
peritoneal cavities, and abdominal mesenteries of mice in-
jected intravenously with B16F10 melanoma cells. Given that
survival of early metastatic colonies is a highly inefficient
process [6], these results imply that a significant number of
injected cells escaped mechanical arrest in the pulmonary
microcirculation and landed successfully in other organs and
tissues. Therefore, neoplastic cell arrest in the first capillary
bed encountered could be a significantly less efficient process
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than previously thought. Our recent results, showing that
metastatic cancer cells are capable of avoiding mechanical
entrapment by adjusting their shape and passing through
narrow microcirculatory compartments [9], further support
this idea.
Taken together, these observations led us to hypothe-
size that mechanical factors alone are not sufficient for the
ultimate tumor cell arrest in target organ circulation, and
that specific adhesive interactions between metastatic cells
and blood vessel endothelia are necessary for malignant
cell arrest in microvessels. Indeed, many metastatic cells
arrested in lung circulation, as shown recently by Al-Mehdi
et al. [3] and Wong et al. [4], reside in precapillary arterioles
of calibers far exceeding tumor cells in size. Similarly, Orr
and Wang [10] documented colon carcinoma cell arrest in
precapillary hepatic vessels larger than tumor cell diame-
ters. In our experiments employing porcine dura mater
model [11], we observed frequently stable breast and
prostate cancer cell adhesion within 50– to 100-mm–wide
precapillary arterioles [9,11,12]. These facts demonstrate
unambiguously that blood-borne malignant cells could be
arrested in a variety of organs and tissues through specific
adhesive interactions with vessel walls in the absence of
mechanical entrapment.
Further, in vitrometastatic breast and prostate carcinoma
cell adhesion to microvascular endothelium derived from
anatomic sites, including the lungs and bone marrow, is
mediated largely by interactions between cancer-associated
Thomsen-Friedenreich (TF) glycoantigen (Galb1-3GalNAc)
and b-galactoside–binding lectin galectin-3 [9,11–17]. We
also demonstrated that in vitro TF antigen/galectin-3 inter-
actions could be disrupted efficiently using function-blocking
antibodies against galectin-3 [13,17] and TF antigen [12,15],
or small-molecular-weight carbohydrate-based inhibitors
specifically targeting b-galactoside–mediated adhesion
such as modified citrus pectin (MCP) and lactulosyl-L-leucine
(N-(1-deoxy-4-O-(b-D-galactopyranos-1-yl)-D-fructofuranos-
1-yl)-(S)-2-amino-4-methylpentanoic acid) [15–17]. Thus,
to test our hypothesis, we investigated in vivo patterns of
organ-to-organ distribution of fluorescently labeled breast
and prostate cancer cells, injected intravenously in mice.
In the same model, we determined whether blocking of
b-galactoside–mediated adhesion modified the formation
of metastatic deposits in target organ microvasculature.
Materials and Methods
Antibodies, Chemicals, and Reagents
TIB-166, H18/7, DREG56, and WAPS 12.2 hybridoma
cell lines, producing function-blocking monoclonal anti-
bodies directed against galectin-3, E-selectin, L-selectin,
and P-selectin, respectively, were obtained from ATCC
(Manassas, VA). The JAA-F11 hybridoma producing anti-
TF antigen mAb [18] was kindly provided by Dr. Kate
Rittenhouse-Olson (State University of New York, Buffalo,
NY). All hybridoma cell lines were grown using exactly
the same media composition [RPMI 1640 medium supple-
mented with L-glutamine, 10% fetal bovine serum (FBS), so-
dium pyruvate, and nonessential amino acids]. Thus, when
conditioned supernatants were used in in vivo metastatic
deposit formation assay, they served as negative controls
to each other. MCP and lactulosyl-L-leucine were obtained
as described previously [19–22]. All other chemicals and
reagents, unless otherwise specified, were from Sigma (St.
Louis, MO).
Cancer Cell Lines and Cultures
The MDA-MB-435 human breast carcinoma cell line
was kindly provided by Dr. Janet E. Price (M. D. Anderson
Cancer Center, Houston, TX). The DU-145 human prostate
carcinoma cells were purchased from ATCC. The RPMI
1640 medium supplemented with L-glutamine, 10% FBS,
sodium pyruvate, and nonessential amino acids was used
for tumor cell lines.
In Vivo Metastatic Deposit Formation Assay
Six-week–old male (for prostate cancer experiments) or
female (for breast cancer experiments) HsdIcr:Ha(ICR)-scid
mice (Harlan, Indianapolis, IN) were used in this study, in
accordance with the University of Missouri–approved ani-
mal care protocol. Prior to intravenous injection, cancer cells
were prelabeled for 5 minutes with 3 mg/ml solution of
acridine orange in RPMI 1640 medium, rinsed three times
with serum-free RPMI 1640 medium, and dissociated from
plastic using a nonenzymatic cell dissociation reagent
(Sigma). We demonstrated previously that labeling tumor
cells with acridine orange does not affect their adhesive
behavior in short time experiments [12]. Immediately follow-
ing the dissociation, tumor cells were resuspended using
one of the following: 1) complete RPMI 1640 medium
(control); 2) complete RPMI 1640 medium supplemented
with MCP (0.25% wt/vol final concentration); 3) complete
RPMI 1640 medium supplemented with lactulosyl-L-leucine
(2 mM final concentration); or 4) undiluted conditioned
supernatant containing a corresponding function-blocking
antibody directed against galectin-3, TF antigen, or E-selectin,
L-selectin, or P-selectin, and pipetted to produce a single
cell suspension. All subsequent manipulations with cancer
cells were performed using the same media composition. To
remove any remaining cell clumps, the tumor cell suspen-
sion was filtered through a 20-mm nylon mesh, and adjusted
to contain 5  106 cells/ml. Next, 200 ml (1  106 cells) of a
single-cell suspension of fluorescently labeled MDA-MB-435
or DU-145 cells was injected into a lateral tail vein of the
experimental animal. Three hours postinjection, the animals
were euthanized, and internal organs [lung, bones (verte-
brae and sternum), liver, spleen, kidney, thyroid gland, and
brain] were removed, examined by epifluorescence micros-
copy, and photographed using a QICAM high-performance
digital CCD camera (Quantitative Imaging Corporation, Bur-
naby, Canada). At least two identical experiments were
performed for each experimental set-up. In each animal,
subpleural metastatic deposits were scored in four random
observation fields. The results were calculated and pre-
sented as mean ± SD.
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Results and Discussion
Metastatic Cell Arrest in the First Capillary Bed Encountered
Is Less Efficient than Previously Thought
To test the hypothesis that a significant number of circu-
lating neoplastic cells are capable of escaping mechanical
entrapment in the first capillary bed encountered, we inves-
tigated in vivo patterns of organ-to-organ distribution of
intravenously injected fluorescently labeled breast (MDA-
MB-435) and prostate (DU-145) cancer cells. Three hours
postinjection, numerous metastatic cells landed in the lungs
(Figure 1A). However, as predicted, a significant number of
tumor cells avoided arrest in lung circulation and lodged in
bones (Figure 1, B and C). In addition, selected neoplastic
cells were found in other organs such as the kidneys and
thyroid gland (Figure 1, D and E ). Of note, our experiments
yielded comparable metastatic deposit counts in the lungs
and bones (vertebrae), which did not differ significantly from
each other (Figure 1F ). These results demonstrate that
neoplastic cell arrest in the first capillary bed encountered
(lung) is less efficient than previously thought, suggesting
that mechanical entrapment due to size limitation is not the
ultimate cause of tumor cell arrest in lung.
Thus, we have reasoned that specific adhesive interac-
tions between metastatic cells and microvascular endothe-
lia, rather than mechanical factors, could play the foremost
role in mediating tumor cell arrest in distant organ micro-
vessels. Recent results from our groups revealed that, in
vitro, metastatic breast and prostate carcinoma cell adhe-
sion to microvascular endothelial cells derived from various
anatomic sites, including the lungs [17] and bone marrow
[13,15], mediated largely by interactions between cancer-
associated TF glycoantigen and b-galactoside–binding lec-
tin galectin-3 [13–17]. Therefore, we investigated next
whether blocking TF antigen and galectin-3 with monoclo-
nal antibodies would modify the formation of breast and
prostate cancer metastatic deposits in the lungs and bones
in vivo.
Anti-TF Antigen and Anti–Galectin-3 Antibodies Inhibit Lung
and Bone Metastatic Deposit Formation
In vitro, TF antigen/galectin-3 interactions mediate hetero-
typic adhesion between tumor cells and endothelia [9,15–17],
as well as malignant cell homotypic aggregation with each
other [9,15–17,23], both of which may contribute to meta-
static cell arrest in microcirculation [9]. Further, galectin-3
expressed on both neoplastic and endothelial cells partic-
ipates in these processes [9,17]. Thus, we investigated next
whether blocking TF antigen and galectin-3 with monoclonal
antibodies modified the formation of breast and prostate
cancer metastatic deposits in the lungs and bones in vivo.
In these experiments, conditioned supernatants of hybrid-
oma cultures were used as function-blocking antibodies. All
five hybridoma cell lines used in this study were grown using
exactly the same media composition (RPMI 1640 medium
supplemented with L-glutamine, 10% FBS, sodium pyruvate,
and nonessential amino acids). The ability of TIB-166 and
JAA-F11 antibodies, directed against galectin-3 and TF anti-
gen, respectively, to inhibit tumor cell adhesion to the endo-
thelium in vitro was demonstrated previously [12,15,17]. The
supernatants of hybridomas producing antibodies directed
against E-selectin, L-selectin, and P-selectin were tested for
their ability to inhibit the rolling of peripheral mononuclear
cells on TNF-a– or histamine-activated endothelial mono-
layers and P-selectin–coated plates, respectively. Conse-
quently, all antibodies were applied at the concentrations
exceeding their related in vitro IC50 at least 50- to 100-fold.
Thus, when conditioned supernatants were used in in vivo
metastatic deposit formation assay (Figures 2 and 3), they
served as negative controls to each other.
The results of these experiments demonstrated that
blocking either TF antigen or galectin-3 with monoclonal anti-
bodies dramatically inhibits metastatic deposit formation in
both the lung and bones (Figure 2). It appears that efficient
blockage of TF antigen/galectin-3–mediated adhesion pre-
cludes almost completely metastatic breast and prostate
cancer cell arrest in distant organ microvessels. This out-
come indicates that such arrest is consequent to adhesive
interactions between tumor cells and microvascular endo-
thelia, and not mechanical entrapment.
Intravenous injection of the fluorescently labeled tumor
cells yields consistently reproducible counts of subpleural
metastatic deposits in mouse lungs, and allows for assessing
the inhibitory effect of various agents on this process. Thus,
in the next series of experiments, we focused specifically on
quantifying the effect of several potential antiadhesion com-
pounds on subpleural metastatic deposit formation.
Figure 1. A significant fraction of intravenously injected cancer cells escapes
mechanical entrapment in the first capillary bed encountered (lung) and
reaches other organs and tissues. Metastatic deposits of fluorescently labeled
cancer cells (DU-145 human prostate carcinoma shown) formed in vivo 3
hours postinjection of 1 106 cells in the lungs (A), vertebrae (B), sternum (C),
kidney (D), and thyroid gland (E). Scale bar, 500 m. (F) Metastatic deposit
counts in lungs and bones (vertebrae). Bars, mean ± SD.
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Breast and Prostate Cancer Cell Arrest in Murine Lung
Supported Predominantly by -Galactoside–Mediated
Interactions
In these experiments, in addition to anti-TF antigen
and anti–galectin-3 antibodies, two small-molecular-weight
carbohydrate-based compounds, lactulosyl-L-leucine and
MCP, were tested along with the function-blocking antibodies
directed against E-selectin, L-selectin, and P-selectin for
their ability to inhibit the formation of subpleural metastatic
deposits. Of these, lactulosyl-L-leucine and MCP bind galec-
tins and inhibit b-galactoside–mediated adhesion by mim-
icking essential structural features of naturally occurring
carbohydrate structures [15,16]. For example, lactulosyl-L-
leucine specifically blocks galectin-3 by mimicking cancer-
associated TF antigen [15]. Importantly, these carbohydrate-
based galectin-3 inhibitors were already shown to reduce
efficiently both the incidence and number of spontaneous
breast and prostate carcinomametastases in vivo [16,20,22].
The results of these experiments demonstrated that all
four compounds targeting b-galactoside–mediated interac-
tions (anti-TF antigen, anti–galectin-3, lactulosyl-L-leucine,
and MCP) inhibited almost completely the formation of breast
and prostate carcinoma subpleural metastatic deposits in
vivo (Figure 3). Specifically, anti-TF mAb, anti –galectin-
3 mAb, lactulosyl-L-leucine, and MCP inhibited subpleural
metastatic deposit formation by 99.3 ± 1.11%, 97.5 ± 2.26%,
96.3 ± 3.21%, and 92.7 ± 4.88% (mean ± SD), and 99.8 ±
0.32%, 97.6±0.96%,94.8± 6.65%, and91.7±7.30% (mean±
SD) of breast and prostate carcinoma cells, respectively.
Thus, MDA-MB-435 and DU-145 metastatic cell arrest in
lung microvessels is mediated predominantly by cancer-
associated TF glycoantigen and galectin-3. Furthermore,
although the inhibitory effect of these compounds on bone
colonization was not quantified, our results (Figure 2, d– f )
strongly suggest that b-galactoside–mediated intercellular
adhesion is likely to play a pivotal role in supporting the
homing of breast and prostate carcinoma cells to the bone
microvasculature as well. However, in addition to inhibiting
cell-to-cell adhesion, blocking galectin-3 may potentially
increase tumor cell susceptibility to apoptosis including
anoikis and, therefore, affect their viability and impact experi-
mental outcomes. To ensure that the inhibitors of TF antigen/
galectin-3 interactions do not affect cancer cell viability, we
performed a series of control experiments, in which single-
cell suspensions of tumor cells were incubated for 3 hours at
37jC in 5% CO2 atmosphere without (control) or with anti-
TF antigen, anti–galectin-3, lactulosyl-L-leucine, and MCP at
the same concentrations as in in vivo experiments. To pre-
vent cancer cell adhesion to the plastic, these experiments
were conducted in ultralow adhesion plates. The percentage
of viable cells determined by a Trypan blue dye exclusion
after 3 hours of incubation was as follows: control, 94.7 ±
4.8%; JAA-F11 (anti-TF antigen), 92.3 ± 5.2%; TIB-166
(anti–galectin-3), 90.9 ± 8.1%; lactulosyl-L-leucine, 92.3 ±
7.9%; and MCP, 88.7 ± 7.5% (mean ± SD). These results
indicate that the galectin-3 and TF antigen inhibitors used in
this study do not significantly affect tumor cell viability and,
therefore, their effects on metastatic deposit formation in this
experimental system could be attributed entirely to their
antiadhesion effect. In contrast, it appears that selectins do
not play a major role in breast and prostate carcinoma cell
Figure 2. The effect of anti-TF antigen and anti –galectin-3 antibodies on metastatic deposit formation in the lungs and bones in vivo. Both anti-TF antigen and
anti –galectin-3 function-blocking monoclonal antibodies dramatically inhibit metastatic deposit formation in mouse lungs (top panel) and bones (bottom panel) in
vivo. Scale bar, 500 m.
Figure 3. The effect of various function-blocking monoclonal antibodies and
carbohydrate-based compounds on subpleural metastatic deposit formation
of DU-145 human prostate carcinoma and MDA-MB-435 human breast
carcinoma cells. Anti-TF antigen, anti –galectin-3, lactulosyl-L-leucine, and
MCP inhibit >90% subpleural metastatic deposit formation of prostate (closed
bars) and breast (open bars) cancer cells in vivo, whereas all three of
antiselectin antibodies tested fail to affect this process significantly. Bars,
mean ± SD.
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arrest in murine lung microvasculature. All three antiselectin
antibodies tested failed to affect this process significantly
(Figure 3). These results are consistent with observations by
Satoh et al. [24] that multiple prostate carcinoma cell lines
lack selectin-mediated adhesion despite expression of a
sialyl-Lewis(x) antigen (the ligand for endothelial selectins).
However, selectin-mediated adhesion plays an important
role in colon cancer cell arrest in hepatic microvessels
(Ref. [10] and reviewed in Ref. [25]). Similarly, in different
types of cancer, other adhesion molecules could be crucial
for metastatic cell lodging in their related target tissues.
The notion that mechanical entrapment is the primary
means of metastatic cell arrest in distant organ microvessels
is based largely on the fact that blood-borne metastatic cells
lodge predominantly in precapillary vessels and capillaries
(reviewed in Refs. [1,2]). In the absence of efficient inhibitors
of tumor–endothelial cell adhesion, this phenomenon was
interpreted by many as an evidence of tumor cell mechanical
arrest in target organ microvessels. Here, we demonstrate
that efficient blocking of tumor–endothelial cell adhesion
precludes almost completely metastatic cell arrest and re-
tention in lung and bones. It appears that mechanical tumor
embolism does not occur when intercellular adhesive inter-
actions are blocked, indicating that mechanical entrapment
is not sufficient for the ultimate tumor cell arrest in microcir-
culation. Thus, we suggest that mechanical factors play a
rather supportive role in mediating metastatic cell lodging in
distant organs (i.e., mechanical factors reduce tumor cell
traveling velocities and prolong neoplastic cell contact with
microvascular endothelium, increasing greatly the chances
for adhesive interactions to take place). However, as sug-
gested previously by Fidler and Talmadge [26] in murine
melanomamodel, mechanical factors may cause an arrest of
multicellular aggregates. We recently reported that both
breast and prostate cancer cells form such aggregates
intravascularly at the sites of their primary attachment to
the endothelium [9] and, lately, the formation of multicellular
metastatic deposits in vivo by human fibrosarcoma cells was
elegantly shown by Yamamoto et al. [27] using color-coded
fluorescently labeled cancer cells.
Here, we propose the model whereby mechanical and
adhesive factors act cooperatively to support metastatic cell
arrest in target organ microvessels. On the molecular level,
we believe that TF antigen/galectin-3 interactions represent
some of the earliest events in a multistep cell-to-cell adhe-
sion process. Most likely, these carbohydrate–lectin inter-
actions, which are rather weak and transient in nature, are
important in initiating tumor–endothelial cell adhesive cas-
cade and in mediating subsequent integrin-mediated stabi-
lizing steps, which further determine the fate of metastatic
deposits and organ specificity of hematogenous cancer
metastasis. For example, the results from Wang et al. [28]
demonstrated an important role for a3b1 integrin in mediating
the pulmonary arrest of several cancer cell lines, including
the MDA-MB-435 breast carcinoma cells, which were used in
this study. Further, most recently, Fukushi et al. [29] showed
that galectin-3 physically associates with a3b1 integrin at
the endothelial cell membrane. Taken together, these facts
suggest a logical chain of subsequent molecular events,
whereas TF antigen expressed on tumor cells mediates
galectin-3 clustering on endothelial cell surfaces [9,12,15]
and initiates transient adhesion, which is stabilized by a3b1
integrin engagement and association with galectin-3. The
galectin-3–mediated involvement of a3b1 integrin provides
for both the means of anchoring galectin-3 at the cell
membrane and for initiating multiple downstream signal-
ing cascades. In our opinion, this model offers answers to
important questions regarding the microvascular patho-
physiology of hematogenous cancer spread, and provides
further justification for the unification of the seed and soil and
mechanical trapping theories of cancer metastasis.
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